• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Commentary: Freestyle root replacement is not free and long-term radiographic surveillance should be in style
Holmgren-Dagnegard and colleagues1 present a cross-sectional, radiographic study of a large population of patients  who had undergone stentless xenograft (Freestyle; Medtronic Incorporated, Minneapolis, Minn) aortic root replacement at 2 institutions (Rigshospitalet, University Hospital of Copenhagen and Montreal Heart Institute, University of Montreal).1 They performed transthoracic echocardiography and contr ast-enhanced, echocardiography-gated 4-dimensional cardiac computed tomography (4DCT) on all included patients (N = 253) and present data on the prevalence of various established, long-term anatomic abnormalities...
Source: The Journal of Thoracic and Cardiovascular Surgery - May 31, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Charles M. Wojnarski Tags: Commentary Source Type: research

Structural abnormalities after aortic root replacement with stentless xenograft
In complex and high-risk aortic root disease, the porcine Freestyle Stentless bioprosthesis ® (Medtronic Incorporated, Minneapolis, Minnesota, US) is an important surgical treatment option. We aimed to determine prevalence and clinical impact of structural and functional abnormalities after full-root Freestyle implantation.
Source: The Journal of Thoracic and Cardiovascular Surgery - May 11, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Hanna Sofia Holmgren Dagneg ård, Per Ejlstrup Sigvardsen, Nikolaj Ihlemann, Klaus Fuglsang Kofoed, Ismail El-Hamamsy, Kirstine Bekke, Jan Brink Valentin, Laurence Lefebvre, Søren Paaske Johnsen, Lars Søndergaard, Jens Teglgaard Lund, Morten Holdgaard S Source Type: research

Commentary: Regression or progression: Hominum, bovinum, porcinum?
This report mimics another recent study in which they compared those with and without a root abscess, treated predominantly with either a stented or stentless bioprosthesis.2 These reports are similar in that they cover the same time period and included largely the same patients.
Source: The Journal of Thoracic and Cardiovascular Surgery - October 10, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Thomas G. Gleason Tags: Commentary Source Type: research

The thrombocytopenia conundrum after aortic bioprosthetic implantation: Do we really need to solve it?
The problem of thrombocytopenia after aortic valve replacement (AVR) with biological prostheses was identified more than 10  years ago. In a series of 20 patients receiving a Freedom Solo stentless pericardial valve (FSSP; LivaNova, Saluggia, Italy), Yekebaran and colleagues1 first observed a significant reduction of postoperative platelet count without any clinical impact. Subsequently, various studies on this subject confirmed this initial observation. In 2012, we studied this problem, comparing 3 bioprostheses used for AVR: the FSSP and 2 stented valves, Mitroflow pericardial (LivaNova) and Mosaic porcine (Medtronic, Minneapolis, Minn).
Source: The Journal of Thoracic and Cardiovascular Surgery - August 10, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Igor Vendramin, Uberto Bortolotti Tags: Letter to the Editor Source Type: research

Commentary: Are the early benefits of thoracic endovascular aortic repair in complicated type B dissection durable through time?
The introduction of thoracic endovascular aortic repair (TEVAR) procedures have revolutionized the treatment of complicated type B aortic dissection. Perioperative mortality rates have declined from 30% to 50% for a classic open repair to 10% in the TEVAR era.1 Although the benefits of TEVAR to decrease early morbidity and mortality are indisputable, data on late outcomes remain limited. Bavaria and colleagues2 report good clinical outcomes at 5  years in a multicenter nonrandomized trial of 50 patients with acute type B aortic dissection with malperfusion treated with the Valiant Captivia device (Medtronic, Minneapolis, Minn).
Source: The Journal of Thoracic and Cardiovascular Surgery - April 22, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Francois Dagenais Tags: Commentary Source Type: research

Commentary: The tortoise and the hare: Does speed matter in pediatric VAD therapy?
The arrival of the HeartWare HVAD (Medtronic, Minneapolis, Minn) had an immediate impact on the pediatric ventricular assist device (VAD) community. The HVAD became the dominant VAD used to support children weighing ≥20 to 25 kg.1 Although the use of this device in children is associated with comparable survival to that seen in case-matched young adults, the hemocompatibility and neurologic event rates have room for improvement, especially in children
Source: The Journal of Thoracic and Cardiovascular Surgery - November 26, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Chet R. Villa, David L.S. Morales Tags: Commentary Source Type: research

Commentary: Bleeding events with novel bioprostheses: Still a mystery
In this report, the authors showed that the Medtronic Avalus valve had rates of adverse events that they considered comparable with those of other contemporary pericardial aortic valves (all-cause death was 7.2%, valve-related in 1.1%), but greater-than-expected bleeding rates.
Source: The Journal of Thoracic and Cardiovascular Surgery - October 23, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Manuel J. Antunes Tags: Commentary Source Type: research

Commentary: Transcatheter aortic valve –in–transcatheter aortic valve replacement—Are we learning more and knowing less?
With both Edwards Sapien 3 (Edwards Lifesciences, Irvine, Calif) and Medtronic CoreValve Evolut R (Medtronic, Minneapolis, Minn) valves now commercially available for use in low-risk patients, transcatheter aortic valve replacement will quickly become the procedure of choice for virtually every patient with severe aortic stenosis, independent of age, risk, or valve pathology (save for endocarditis). As its use increases in those with longer life expectancy, some valves will inevitably fail. On the heels of previous studies in which their group evaluated the hemodynamic properties of transcatheter valves placed both as isol...
Source: The Journal of Thoracic and Cardiovascular Surgery - October 8, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Gaetano Paone, Adam B. Greenbaum Tags: Commentary Source Type: research

Blood trauma potential of the HeartWare Ventricular Assist Device in pediatric patients
Mechanical circulatory support has become a standard therapy for adult patients with end-stage heart failure. For pediatric patients, technologic development lags behind with no currently approved implantable rotary blood pump. As an alternative, the HeartWare Ventricular Assist Device (Medtronic, Minneapolis, Minn), originally designed for adults, is increasingly used in pediatric patients. The aim of this multicenter study was to assess in silico, in  vitro, and in vivo the blood trauma potential of this pump in pediatric application.
Source: The Journal of Thoracic and Cardiovascular Surgery - July 18, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Marcus Granegger, Bente Thamsen, Thomas Schl öglhofer, Selina Lach, Andreas Escher, Thorsten Haas, Mirko Meboldt, Martin Schweiger, Michael Hübler, Daniel Zimpfer Tags: Mechanical Circulatory Support Source Type: research

Lessons learned from Melody valve retrieved at transplantation
In their Letter to the Editor, Honjo and co-authors1 provide an update on a patient who underwent common atrioventricular valve replacement with a stented bovine jugular vein graft (Melody, Medtronic, Minneapolis, Minn) valve. At the time of cardiac transplantation, the Melody valve was removed.
Source: The Journal of Thoracic and Cardiovascular Surgery - June 4, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Sitaram M. Emani Tags: Letter to the Editor Source Type: research

New trends in cardiac surgery: Toward a less-invasive surgical procedure
We read with interest the article by Quan and colleagues.1 The authors report on a 41-year-old man with advanced cardiomyopathy complicated with cardiogenic shock that was successfully treated. The article highlights 2 aspects: (1) the concomitant execution of venoarterial extracorporeal membrane oxygenation implantation and a transvenous atrial septostomy; and (2) in a delayed surgical procedure, the insertion of a left ventricular assist device (LVAD) (HeartWare HVAD, Medtronic, Minneapolis, Minn) using minimal access surgery (left median type upper ministernotomy and a left anterior minithoracotomy) in association with ...
Source: The Journal of Thoracic and Cardiovascular Surgery - March 11, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Cipriano Abad, Stefano Urso, Bernardino Clavo Tags: Letter to the Editor Source Type: research

A bridge to heart transplant: Systemic atrioventricular valve replacement with a Melody valve in an infant with a single-ventricle physiology
We recently reported a case of atrioventricular valve (AV) replacement with a Melody valve (Medtronic, Minneapolis, Minn) in a 3-month-old, 3.2-kg infant with unbalanced atrioventricular septal defect, dominant left ventricle who presented with severe AV regurgitation and borderline ventricular function.1 In this letter, we would like to report an update on the Melody valve status and the patient's clinical course until successful heart transplantation at 13  months after the AV replacement.
Source: The Journal of Thoracic and Cardiovascular Surgery - March 6, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Shuhua Luo, Osami Honjo Tags: Letter to the Editor Source Type: research

Thank you, sir, may I TAVI another: Procedural problems and postoperative complications in SURTAVI
We congratulate the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial Causes of Death Working Group on a fantastic presentation of the first year of data after randomization, presented by Amrane and colleagues1 in this issue of the Journal. Readers will recall that the industry-funded (Medtronic, Minneapolis, Minn) SURTAVI trial enrolled 1660 intermediate-risk patients from June 2012 to June 2016 to receive TAVR with self-expanding valves or surgical aortic valve replacement (SAVR).
Source: The Journal of Thoracic and Cardiovascular Surgery - December 4, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Judson B. Williams, Jeffrey G. Gaca Tags: Editorial Commentary Source Type: research

Commentary: Thank you, sir, may I TAVI another: Procedural problems and postoperative complications in SURTAVI
We congratulate the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial Causes of Death Working Group on a fantastic presentation of the first year of data after randomization, presented by Amrane and colleagues1 in this issue of the Journal. Readers will recall that the industry-funded (Medtronic, Minneapolis, Minn) SURTAVI trial enrolled 1660 intermediate-risk patients from June 2012 to June 2016 to receive TAVR with self-expanding valves or surgical aortic valve replacement (SAVR).
Source: The Journal of Thoracic and Cardiovascular Surgery - December 3, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Judson B. Williams, Jeffrey G. Gaca Tags: Commentary Source Type: research

Betting the trifecta: Gradient, prosthesis –patient mismatch, and durability
In horse-betting parlance, the trifecta is a bet on 3 horses finishing win, place, or show in that order. It has more risk and therefore pays more to the bettor and remains a popular wager. The current article, “Trifecta Has Lower Transvalvular Gradient and Less Prosthetic-Patient Mismatch Than Mosaic Ultra in the Aortic Position: A Prospective Randomized Trial,1” is a prospective single-institution analysis of 90 patients with aortic valvular pathology requiring aortic valve replacement. The purpose o f the study is to compare size for size, 6-month hemodynamic performance of the Trifecta biological valve (St Jude Med...
Source: The Journal of Thoracic and Cardiovascular Surgery - November 16, 2018 Category: Cardiovascular & Thoracic Surgery Authors: George L. Hicks Tags: Editorial Commentary Source Type: research

Pages: 1  2  3  4